Company: RVRC
Filing Date: 2025-08-13
Form Type: S-1/A
Source: 0001213900-25-075747
Chunk: 62

Company: Revium Rx.
Filing Date: 2025-08-13
Form: S-1/A
Chunk 62
---
 Company of all of the outstanding capital stock of LipoVation. Following the closing, 40% of the issued and outstanding shares of
the Company’s Common Stock immediately upon the closing of the Share Exchange were held by the former LipoVation shareholders.

As a result of the Share Exchange, the Company
acquired the business of LipoVation, which became the primary business of the Company. Through LipoVation, the Company is committed to
developing innovative nano-therapeutics and anti-infectives to deliver advanced treatment solutions for diseases with limited or no effective
treatment options

Also, after the closing of the Share Exchange,
the Company discontinued all its efforts to develop a disruptive, methodical and novel proprietary Clinical Decision Support software
(CDS).

<div align='center'>35</div>

Private Placement Offerings

Between December 2020 and August 2022, the Company
conducted a private placement offering (the “First Private Placement Offering”) of units of the Company ’securities,
at the price per unit of $0.80. Each unit (a “Unit” and collectively the “Units”) is comprised of (i) two (2)
shares of the Company’s Common Stock and (ii) one common stock purchase warrant to purchase an additional share of the Company’s
Common Stock, exercisable for a 3-year period from the date of the issuance at a per share exercise price of $0.80. We raised aggregate
gross proceeds of $2,790 thousands from the First Private Placement Offering and issued an aggregate of 6,975,000 shares of Common stock
and warrants to purchase 3,562,500 shares of Common Stock to accredited investors in this First Private Placement Offering.

Between April and December 2023, the Company
conducted another private placement of units of its securities at $3.20 price per unit (the “Second Private Placement Offering”),
where each unit (a “Unit” and collectively the “Units”) comprised of (i) two (2) shares of the Common Stock and
(ii) one common stock purchase warrant to purchase an additional share of the Company’s Common Stock exercisable until December
31, 2026, at a per share exercise price of $2.40. In consideration of proceeds in the amount of $4,631.25 thousands received from the
subscribers in the Second Private Placement Offering, we issued to these investors an aggregate of 2,894,532 of the Company’s Common